Partner with us
Three open research needs, each with a defined first contribution.
The next year is bench work, independent eyes on the data and the first collaborator studies. Here is exactly what would help, what you would receive in return and how to reach the person responsible.
Trustworthy bench measurements
Question. Which measurement limitations could invalidate an interpretation of the first bench results?
First useful contribution. A proposed calibration, timing and uncertainty plan for the bench configuration, written against stated conditions that we share under a short agreement.
Format. A two- to four-page written plan or a 45-minute call, your choice. Credited by name if you wish.
Evidence for lasting benefit
Question. What would distinguish a transient physiological response from meaningful, durable function in brain-health research?
First useful contribution. An endpoint and alternative-explanations review: what would count, what could mislead, and what a later study would need.
Format. A short written review or a call. Your review informs the research-readiness stage and is cited when we publish the study design.
Research readiness done properly
Question. What does a supervised collaborator study need, from risk management to ethical review, before anyone proposes it?
First useful contribution. A checklist of the determinations, documents and reviews required for a first supervised study with an academic or clinical partner.
Format. A call followed by a one-page checklist. Opens the door to a formal advisory or collaborator role.
Open needs 01 and 02 are also posted on the MNEOS program page, where they carry the identifiers OP-01 and OP-02. Point of contact for all three: David Sherrer.
Collaborators
Respond to an open need or propose a study
Tell us which need you are answering, or what you would want to test, in a short non-confidential note. You will hear back from David Sherrer, and we put a mutual agreement in place before anything sensitive is shared in either direction.
The form is hosted by MNEOS, our institutional home, with NeuroClearance preselected. It asks for your name, email, area of interest and a short non-confidential note, gives you a reference number on screen, and delivers directly to David Sherrer. It is for research collaboration only; investor and press inquiries go by email.
Investors
Read the public brief first
The investor brief states the thesis, stage, first use case, working commercial hypothesis and next financed milestone, and explains how to request the private brief. Investor inquiries go directly to the founder, not into a research intake.
Go to the investor briefCommunity
Follow the bench
Plain-language updates when something is measured, published or decided, no more than monthly. Reply to any message to unsubscribe. We never ask for or store health information. Signing up for updates is separate from any inquiry.
Join the updates listEmail buttons open a prefilled message to [email protected]. If your device has no mail client, write to that address with the subject shown. The collaborator form was tested end to end, including delivery of the notification, on October 27, 2026.
Before you write
A few ground rules that protect you.
Your ideas stay yours
If you bring us a collaboration or a technology, your background and your work remain yours. We confirm that in writing before any substantive discussion.
Please do not send
Personal health or medical information about yourself or anyone else; confidential or proprietary technical data; anything you would not want in an ordinary email. We arrange a secure channel when one is needed.
Press and speaking
Approved program description, biography and logo files are on the team page. For interviews or talks, email [email protected] with the subject “Press”.